Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675 is registered in ClinicalTrials.gov with Cumberland Pharmaceuticals as lead sponsor.

NCT NCT03340675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Lead sponsor
Cumberland Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 19, 2020
Completion date
January 23, 2026
Enrollment
46 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathy, dilated, duchenne muscular dystrophy cardiomyopathy